

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM391606

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
US WorldMeds, LLC		07/15/2015	Limited Liability Company: DELAWARE
RECEIVING PARTY DATA			
Name:	CRG Servicing LLC, as Administrative Agent		
Street Address:	1000 Main Street, Suite 2500		
City:	Houston		
State/Country:	TEXAS		
Postal Code:	77002		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	3871489	REVONTO	
Serial Number:	87014902	LUCEMYRA	
Serial Number:	87014920	ORYST	
Serial Number:	87059506	US WORLDMEDS	
Serial Number:	87061459	US WORLDMEDS	
CORRESPONDENCE DATA			
Fax Number:	4156932222		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	4156932000		
Email:	crhem@cooley.com		
Correspondent Name:	Cooley LLP		
Address Line 1:	101 California Street, 5th Floor		
Address Line 4:	San Francisco, CALIFORNIA 94111		
NAME OF SUBMITTER:	C, Rhem		
SIGNATURE:	/CR/		
DATE SIGNED:	07/15/2016		
Total Attachments: 8 source=USWM 3#page1.tif			

CH \$140.00 3871489

source=USWM 3#page2.tif
source=USWM 3#page3.tif
source=USWM 3#page4.tif
source=USWM 3#page5.tif
source=USWM 3#page6.tif
source=USWM 3#page7.tif
source=USWM 3#page8.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

July 15, 2016

WHEREAS, US WORLDMEDS, LLC, a Delaware limited liability company (“*Grantor*”), is party to that certain Security Agreement, dated as of July (as amended, restated, supplemented or otherwise modified from time to time, the “*Security Agreement*”; capitalized terms used herein without definition shall have the meanings set forth in the Security Agreement), among Grantor, the Guarantors from time to time party thereto and CRG SERVICING LLC, as administrative agent and collateral agent (in such capacities, together with its successors and assigns, the “*Administrative Agent*”), pursuant to which Grantor has granted in favor of Secured Parties a lien on all of its personal property, including without limitation the patents and patent applications listed on **Schedule A** hereto, and the trademarks and trademark applications listed on the **Schedule B** hereto; and

WHEREAS, it is a condition to the advance of the loans and other obligations secured by the Security Agreement, that Grantor execute and deliver, and cause to be filed in the U.S. Patent and Trademark Office, this Patent and Trademark Security Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

As collateral security for the payment in full when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, Grantor hereby pledges and grants to the Administrative Agent for the benefit of the Secured Parties a security interest in all of Grantor’s right, title and interest in, to and under all of the following, as collateral security for the prompt and complete payment and performance when due of all the Secured Obligations (as defined in the Security Agreement):

(i) all patents and patent applications, in each case whether now owned by Grantor or hereafter acquired and whether now existing or hereafter coming into existence, including without limitation those listed on **Schedule A** hereto, and all related patents and applications thereto, including all reissuances, continuations, continuations-in-part, revisions, extensions, re-examinations thereof, any patents and patent applications claiming priority to said patents and patent applications or from which said patents and patent applications claim priority, and pending applications associated therewith; and

(ii) all of the trademarks, whether now owned or at any time hereafter acquired, of Grantor that are registered with, or for which applications for registration have been filed with, the United States Patent and Trademark Office, including the trademarks listed on **Schedule B** hereto, and all registrations and pending applications associated therewith (excluding any application for registration of a trademark filed on an intent-to-use basis solely to the extent that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application).

Notwithstanding the foregoing, in the event of any conflict between this Patent and Trademark Security Agreement and the Security Agreement, the Security Agreement shall control.

This Patent and Trademark Security Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application of the laws of any other jurisdiction; *provided that* Section 5-1401 of the New York General Obligations Law shall apply.

[signature to follow]

IN WITNESS WHEREOF, Grantor has caused this Patent and Trademark Security Agreement to be duly executed and delivered as of the day and year first above written.

US WORLDMEDS, LLC, as Grantor

By 

Name: Paul Breckinridge Jones

Title: Chief Executive Officer

**Schedule A
to Patent and Trademark Security Agreement**

PATENTS AND PATENT APPLICATIONS

US Patents

<u>Grantor</u>	<u>Patent/ Patent Application</u>	<u>Registration/ Application No.</u>	<u>Registration/ Filing Date</u>	<u>Expiration Date</u>
US WorldMeds LLC	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	8,975,284	03/10/2015	09/23/2031
US WorldMeds LLC	ORAL FORMULATIONS OF APOMORPHINE AND OTHER DOPAMINE MODULATING AGENTS FOR PATIENT-SPECIFIC PHARMACO-CHRONOTHERAPY TO AMELIORATE OFF-TIMES IN PARKINSON'S DISEASE	62/280,291 (Provisional patent application)	01/19/2016	01/19/2017

Foreign Patents

Grantor	Country	Title	Patent No.	Issue Date	Expiration Date
US WorldMeds LLC	Canada	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2,702,243	Notice of Allowance October 21,2015	—
US WorldMeds LLC	EP	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2 219 605	08/19/15	09/05/28
US WorldMeds LLC	Japan	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	5406197	11/08/13	09/05/28
US WorldMeds LLC	CH (Switzerland)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	DE (Germany)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	ES (Spain)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	FR (France)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	GB (United Kingdom)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	IE (Ireland)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	IT (Italy)	CO-SOLVENT COMPOSITIONS AND METHODS FOR	2219605	08/19/15	09/05/28

		IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS			
US WorldMeds LLC	LU (Luxemborg)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	MC (Monaco)	CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS	2219605	08/19/15	09/05/28
US WorldMeds LLC	EP	COMPOSITION AND METHOD FOR TRANSMUCOSAL DELIVERY OF LOFEXIDINE	09724650.8	3/25/2009 (PCT filing date)	
US WorldMeds LLC	Canada	STABLE LIQUID FORMULATIONS OF BOTULINUM TOXIN	2,342,243	01/14/14	9/09/19
US WorldMeds LLC	EP	STABLE LIQUID FORMULATIONS OF BOTULINUM TOXIN	1 112 082	07/31/02	9/09/19
US WorldMeds LLC	Japan	STABLE LIQUID FORMULATIONS OF BOTULINUM TOXIN	4,557,426	07/30/10	9/09/19
US WorldMeds LLC	Japan	STABLE LIQUID FORMULATIONS OF BOTULINUM TOXIN (Divisional)	5,270,594	05/17/13	3/01/20
US WorldMeds LLC	Korea	STABLE LIQUID FORMULATIONS OF BOTULINUM TOXIN	0,699,756	03/20/07	9/09/19

**Schedule B
to Patent and Trademark Security Agreement**

TRADEMARKS AND TRADEMARK APPLICATIONS

US Trademarks

Grantor	Trademark	Reg. No.	Reg. Date	Renewal Date
US WorldMeds, LLC	REVONTO	3,871,489	02-Nov-2010	Renewal due 11/02/2020
US WorldMeds, LLC	LUCEMYRA	87/014,902	26-Apr-2016 Pending	
US WorldMeds, LLC	ORYST	87/014,920	26-Apr-2016 Pending	
US WorldMeds, LLC	US WORLDMEDS	87/059,506	3-Jun-2016 Pending	
US WorldMeds, LLC	US WORLDMEDS	87/061,459	6-June-2016 Pending	

Foreign Trademarks

Grantor	Country	Trademark	Reg. No.	Reg. Date	Renewal Date
US WorldMeds, LLC	Korea, Republic of	MYOBLOC	40-0783616	23-Mar-2009	Renewal due 03/23/2019
US WorldMeds, LLC	European Community	NEUROBLOC	611384	15-Feb-2000	Renewal due 08/14/2017
US WorldMeds, LLC – License with Eisai Co., Ltd.	Iceland	NEUROBLOC	675/2000	31-May-2000	Renewal due 05/31/2020
US WorldMeds, LLC – License with Eisai Co., Ltd.	Norway	NEUROBLOC	203409	22-Jun-2000	Renewal due 06/22/2020
US WorldMeds, LLC – License with Eisai Co., Ltd.	Switzerland	NEUROBLOC	476.705	04-Apr-2000	Renewal due 04/04/2020
US WorldMeds, LLC – License with Eisai Co., Ltd.	Turkey	NEUROBLOC	2002 9753	29-Apr-2002	Renewal due 04/29/2022
US WorldMeds, LLC	European Community	REVONTO	9008137	27-Sep-2010	Renewal due 04/30/2020
US WorldMeds, LLC	Benelux	SOLSTICENEURO	781112	05-Dec-2005	Renewal due 11/10/2025